36 DIRECTORS’ REPORT Shares under option Unissued ordinary shares of Kazia Therapeutics Limited under option at the date of this report are as follows. All options are unlisted and were issued under the Company’s Employee Share Option Plan. Grant date Expiry date Exercise Price Closing Balance 7 August 2017 7 August 2022 $0.6700 15,500 5 February 2018 5 February 2023 $0.7800 240,000 13 November 2019 13 November 2023 $0.4930 1,200,000 13 January 2020 13 January 2025 $0.8810 200,000 9 November 2020 9 November 2024 $0.8810 800,000 9 November 2020 9 November 2024 $1.1320 1,200,000 4 January 2021 4 January 2025 $1.6900 200,000 9 September 2021 21 June 2026 $1.3700 100,000 16 November 2021 16 November 2025 $1.6900 1,000,000 16 November 2021 16 November 2025 $2.2400 1,500,000 16 November 2021 16 November 2026 $1.5600 800,000 1 February 2022 1 February 2027 $0.9400 1,300,000 24 May 2022 24 May 2027 $0.7800 100,000 8,655,500 No person entitled to exercise the options had or has any right by virtue of the option to participate in any share issue of the company or of any other body corporate. The following ordinary shares of Kazia Therapeutics Limited were issued during the year ended 30 June 2022 and up to the date of this report on the exercise of options granted: 25,000 shares with an exercise price of 0.67 cents with an option grant date of 7 August 2017. Indemnity and insurance of officers The consolidated entity has not indemnified the Directors and Executives of the consolidated entity for costs incurred, in their capacity as a Director or Executive, for which they may be held personally liable, except where there is a lack of good faith. During the financial year, the consolidated entity paid a premium in respect of a contract to insure the Directors and Executives of the consolidated entity against a liability to the extent permitted by the Corporations Act 2001. The contract of insurance prohibits disclosure of the nature of the liability and the amount of the premium. Indemnity and insurance of auditor The consolidated entity has not, during or since the end of the financial year, indemnified or agreed to indemnify the auditor of the consolidated entity or any related entity against a liability incurred by the auditor. During the financial year, the consolidated entity has not paid a premium in respect of a contract to insure the auditor of the consolidated entity or any related entity. Proceedings on behalf of the company No person has applied to the Court under section 237 of the Corporations Act 2001 for leave to bring proceedings on behalf of the company, or to intervene in any proceedings to which the company is a party for the purpose of taking responsibility on behalf of the company for all or part of those proceedings.
RkJQdWJsaXNoZXIy MjE2NDg3